Sotera Health (SHC) Stock: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$18.22
0.10 (0.55%)
▲
5d:
-0.65%
30d:
-3.9%
90d:
+2.02%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
30d
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SHC is fairly valued with market pricing in 0.9% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: SHC is fairly valued with market pricing in 0.9% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.40
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$15.15
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $18.22, which is considered oversold relative to its 30-day fair value range of $18.35 to $19.16. The stock's valuation (Forward PE: 16.9) is in line with its historical norms (16.5). At these levels, the market is pricing in 0.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $17.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.72 (+24.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $17.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.72 (+24.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$18.35 -
$19.16
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.7% below Wall St target ($22.72)
- NEUTRAL: Market pricing in 0.9% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$18.35 -
$19.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$17.99
Resistance Level
$18.95
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.95
Wall Street Target
$22.72
(+24.7%)
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
569.5%
Profit Margin
13.4%
Valuation Premium vs History
+0.9% premium
PE vs Historical
17.0 vs 16.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$18.38
(+1%)
2-Year Target
$18.55
(+2%)
3-Year Target
$18.72
(+3%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
PE COMPRESSION
$18.22
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 9.2%)
$28.53
(+57%)
Base:
(SPY PE: 17.0, Growth: 9.2%)
$23.71
(+30%)
Bear:
(PE: 14.4, Growth: 9.2%)
$20.15
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 32.36 | Current EPS (TTM): $0.56
Bull Case
$38.26
(+110%)
Analyst growth 91.9%, PE expands to 35.6
Base Case
$34.78
(+91%)
Market implied 91.9%, PE stable at 32.4
Bear Case
$12.32
(-32%)
Severe decline -20.0%, PE contracts to 27.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 9:06 PM ET
Data refreshes hourly during market hours. Next update: 10:06 PM
Data refreshes hourly during market hours. Next update: 10:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 49 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 53 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 48 HOLD |
|
LH
Laboratory Corporation o… |
STRONG BUY
20 analysts |
$345 | 67 BUY |
